TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product. The stem cell programmes are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory and heart diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.

Cx601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. The product has met the primary endpoint of this trial at Week 24 of treatment which will allow for filing for European marketing authorisation in the first quarter of 2016. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cardiac stem cell product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Additional planned projects are the clinical evaluation of AlloCSC-01 in the chronic setting, and the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI.

TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.




Latest News

20 July 2016 - Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix (EN - NL)

5 July 2016 - Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR)

5 July 2016 - TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms (EN - NL - FR)

17 June 2016 - TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction (EN - NL - FR)

16 June 2016 - TiGenix CEO Eduardo Bravo assumes leadership of European Biopharmaceutical Enterprises (EBE) (EN - NL - FR)


Company slide deck

2016 - Corporate Presentation

Management presentations

Full Year 2015 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014